Background-Mitochondrial compromise is a fundamental contributor to heart failure. Recent studies have revealed that several surveillance systems maintain mitochondrial integrity. The present study evaluated the role of mitochondrial AAA+ protease in a mouse model of pressure overload heart failure. Methods and Results-The fluorescein isothiocyanate casein assay and immunoblotting for endogenous mitochondrial proteins revealed a marked reduction in ATP-dependent proteolytic activity in failing heart mitochondria. The level of reduced cysteine was decreased, and tyrosine nitration and protein carbonylation were promoted in Lon protease homolog (LONP1), the most abundant mitochondrial AAA+ protease, in heart failure. Comprehensive analysis revealed that electron transport chain protein levels were increased even with a reduction in the expression of their corresponding mRNAs in heart failure, which indicated decreased protein turnover and resulted in the accumulation of oxidative damage in the electron transport chain. The induction of mitochondria-targeted human catalase ameliorated proteolytic activity and protein homeostasis in the electron transport chain, leading to improvements in mitochondrial energetics and cardiac contractility even during the late stage of pressure overload. Moreover, the infusion of mitoTEMPO, a mitochondria-targeted superoxide dismutase mimetic, recovered oxidative modifications of LONP1 and improved mitochondrial respiration capacity and cardiac function. The in vivo small interfering RNA repression of LONP1 partially canceled the protective effects of mitochondria-targeted human catalase induction and mitoTEMPO infusion. Conclusions-Oxidative post-translational modifications attenuate mitochondrial AAA+ protease activity, which is involved in impaired electron transport chain protein homeostasis, mitochondrial respiration deficiency, and left ventricular contractile dysfunction. Oxidatively inactivated proteases may be an endogenous target for mitoTEMPO treatment in pressure overload heart failure. (Circ Heart Fail. 2014;7:500-509.)
M
arked improvements have been achieved in survival rates after adverse cardiovascular events during the past several decades. However, subsequent heart failure still remains a public health problem. Although significant advances have been made in the management of heart failure mainly through neurohumoral blockade, which prevents cardiac remodeling with drugs that act on the renin-angiotensin-aldosterone system or adrenergic system, mortality and morbidity in patients with heart failure still remain high. Therefore, a novel therapeutic approach is needed. Mitochondrial dysfunction is involved in the pathogenesis of numerous diseases including heart failure. Impaired ATP production and subsequent cardiac energy compromise are fundamental contributors to the development of heart failure. Moreover, mitochondria play a central role in metabolism, oxidative stress, calcium homeostasis, and cell death, all of which are pathogenic contributors to heart failure.
Clinical Perspective on p 509
Mitochondrial quality control systems have been identified at the protein and organelle levels. 1, 2 We previously reported that the autophagic degradation of mitochondria was attenuated by an inhibitory protein-protein interaction between Parkin and cytosolic p53, which contributed to declines in mitochondrial integrity and cardiac contractility in a mouse model of heart failure induced by doxorubicin treatment or cardiac aging. 3 At a basal level, proteolytic degradation is important to maintain the dynamic equilibrium of mitochondrial proteins and destroy damaged proteins. As the main pathway for intramitochondrial protein degradation, the mitochondrial protease is required to sustain biological processing in mitochondria. Mitochondrial proteases are energy-dependent proteases containing conserved ATPase modules that are characteristic of the AAA+ family. 4 Two soluble proteases, the Lon protease and ClpXP protease, are present in the mitochondrial matrix, and 2 proteolytic complexes, m-AAA and i-AAA metalloproteases, are anchored within the inner mitochondrial membrane, which exposes their catalytic domains to the matrix and intermembrane space, respectively. 5 Lon protease homolog (LONP1), the most abundant AAA+ protease in cardiac mitochondria, 6, 7 forms soluble heptameric ring-shaped assemblies with serine protease activity within the mitochondrial matrix.
8 LONP1 was previously shown to degrade various misfolded and oxidatively damaged matrix and inner membrane proteins, thereby preventing their deleterious accumulation. 7, 9 Despite the recognition of proteomic alterations in mitochondrial in heart failure, factors that regulate the rate and mechanisms of mitochondrial protein degradation under physiological and pathological conditions remain obscure.
The present study examined the function of AAA+ mitochondrial protease in a mouse model of pressure overload heart failure after transverse aortic constriction (TAC). The measurement of ATP-dependent proteolytic activity in isolated mitochondria revealed marked reductions in mitochondrial protease activity. The protein carbonylation and tyrosine nitration of LONP1 were promoted in failing heart mitochondria, and the induction of mitochondria-targeted human catalase (mCAT) in failing hearts recovered protease activity. These results suggested that oxidative post-translational modifications (OPTM) contributed to the proteolytic deficit of AAA+ proteases. OPTM-mediated protease dysfunction was closely associated with declines in electron transport chain (ETC) protein homeostasis, mitochondrial energetics, and left ventricular contractility. Moreover, the infusion of mitoTEMPO, a mitochondria-targeted superoxide dismutase mimetic, improved mitochondrial respiration capacity and cardiac function at least partially through the improvement of mitochondrial protease activity in heart failure. A, The fluorescein isothiocyanate casein assay was performed to assess ATP-dependent proteolytic activity of isolated heart mitochondria 2 and 8 weeks after the TAC operation (n=6-8 per group, duplicate experiments). B, Isolated mitochondria from sham-or TAC-operated hearts were incubated in ATP-containing buffer for 12 hours, followed by immunoblotting to assess the ATP-dependent degradation of endogenous COX5a protein. Data are shown as the means±SD (*P<0.05; **P<0.01). ns indicates not significant; and PI, protease inhibitor. Oxidative stress promoted oxidative modifications of mitochondrial AAA+ protease Lon protease homolog (LONP1) in heart failure. A, Real-time polymerase chain reaction assessing the expression of AAA+ proteases in sham-and transverse aortic constriction (TAC)-operated mice at 8 weeks (n=6 per group). B, LONP1 protein expression was assessed by immunoblotting (n=6 per group). C, Hydrogen peroxide production in isolated mitochondria was assessed using the Amplex Red-horseradish peroxidase system. NADH-or succinate-induced hydrogen peroxide production was promoted in TAC-operated failing hearts (n=4 per group, duplicate experiments). D, Mitochondrial protein carbonylation was measured by immunoblotting with an anti-2,4-dinitrophenylhydrazine (DNPH) antibody (n=4 per group). E, The extent of cysteine reduction in LONP1 was evaluated with iodoacetamide. Reduced LONP1 protein levels were normalized by the total LONP1 protein level (n=4 per group). F, Protein carbonylation on LONP1 was evaluated by immunoblotting with an anti-DNPH antibody in immunoprecipitated samples with an anti-LONP1 antibody (n=4 per group). G, Tyrosine nitration on LONP1 was evaluated by immunoblotting with an antinitrotyrosine antibody in immunoprecipitated samples with an anti-LONP1 antibody (n=4 per group). Data are shown as the means±SD (*P<0.05; ** P<0.01; *** P<0.001). AA indicates antimycine A; Rot, rotenone; and Suc, succinate.
Methods
Please see the Data Supplement for additional details. The floxed stop sequence preceding mCAT in the inducible BAC (bacterial artificial chromosomes) model (C57BL/6J background) was kindly gifted from Dr Rabinovitch (University of Washington) 10 ), 13 and epoxomicin (500 μg kg −1 day −1 ) 14 were delivered for 2 weeks with Alzet 1002 pumps. All animal studies were approved by the Animal Care and Use Committee of Kyoto Prefectural University of Medicine. Data are expressed as mean±SD. All statistical analyses were conducted using StatMate III (ATMS, Tokyo, Japan). An unpaired t test was used for comparison between 2 groups, and comparisons among multiple groups were performed with 1-way ANOVA and the Tukey post hoc test. Pearson correlation coefficients were used to assess the relationship between groups in isobaric tags for relative and absolute quantification (iTRAQ) proteomics. P<0.05 was considered to be significant.
Results

Mitochondrial AAA+ Protease Activity Is Impaired in Pressure Overload Heart Failure
We examined the intramitochondrial AAA+ protease activity in TAC-operated heart failure. Isolated mitochondria were incubated with a quenched fluorescein isothiocyanate substrate in ATP-containing buffer to assess their ability to degrade exogenous casein. AAA+ protease activity was attenuated 2 weeks after the TAC operation and further deteriorated in a manner that was dependent on the progression of heart failure ( Figure 1A ). Endogenous protein degradation was also assessed by immunoblotting for COX5a that was previously shown to be a substrate of LONP1. 8 Endogenous protein degradation, which was effectively attenuated by a protease inhibitor, was similarly reduced in heart failure ( Figure 1B) . Although the ubiquitin-proteasome system (UPS) was also reported to be involved in mitochondrial protein homeostasis through a poorly understood mechanism, 6 no significant changes were observed in proteasome activity 2 and 8 weeks after the TAC operation ( Figure I in the Data Supplement).
Enhanced Oxidative Stress Impairs Proteolytic Activity
The expression of AAA+ proteases was not decreased in heart failure ( Figure 2A and 2B). Therefore, we hypothesized that oxidative stress may have contributed to AAA+ protease dysfunction in pressure overload heart failure. Reactive oxygen species (ROS) production in isolated mitochondria was assessed by detecting hydrogen peroxide using the Amplex Red-horseradish peroxidase system. The rate of hydrogen peroxide release measured in the presence of 0.5 mmol/L NADH or 5 mmol/L succinate was promoted in heart failure ( Figure 2C ). The enhanced production of ROS was associated with increased protein carbonylation in mitochondria (Figure 2D) . The ATP-stimulated proteolysis of casein was mostly caused by LONP1 6, 7 ; therefore, we evaluated the extent of oxidative modifications in LONP1. The level of reduced cysteine in LONP1 was decreased in heart failure ( Figure 2E ). We also evaluated tyrosine nitration and protein carbonylation in the proteins immunoprecipitated from mitochondrial extracts using an anti-LONP1 antibody because these oxidative modifications are known to be deleterious to the structures of proteins and lead to the decline of protein function. 15, 16 Nitrotyrosine and carbonylation levels in LONP1 were significantly increased in heart failure ( Figure 2F and 2G). These results indicated that excessive oxidative stress oxidized AAA+ proteases and induced a reduction in proteolytic activity in heart failure. Consistent with this theory, the exposure of isolated mitochondria to exogenous hydrogen peroxide decreased proteolytic activity to degrade fluorescein isothiocyanate -labeled casein ( Figure 3A ). Endogenous protein degradation was also impaired by excessive oxidative stress ( Figure 3B ).
Levels of ETC Proteins Increase, Whereas Their Corresponding mRNA Levels Decrease in Heart Failure
To examine the effects of AAA+ protease dysfunction on mitochondrial remodeling, we analyzed changes in the mitochondrial proteome in pressure overload heart failure. We purified heart mitochondria and performed iTRAQ that enabled the simultaneous identification and relative quantification of mitochondrial proteins through isobaric peptide tagging (Figure II in the Data Supplement). Three groups of animals were examined: sham-operated mice (sham), TAC-operated mice at 2 weeks, and TAC-operated mice at 8 weeks, and samples of TAC-operated mice at 2 weeks and TAC-operated mice at 8 weeks were compared with sham samples (Table I in the Data Supplement). A total of 7925 iTRAQ-labeled peptides that mapped to a total of 464 proteins were identified and quantified from purified heart mitochondria. Differences between 2 two-group comparisons were displayed as a scatter image, revealing a roughly similar pattern of TAC-induced changes ( Figure 4A ). In contrast, the mRNA and protein levels of individual genes rarely correlated in both TAC-operated mice at 2 weeks and TAC-operated mice at 8 weeks. ETC protein levels were higher in spite of rare alterations or reductions in mRNA levels ( Figure 4B ; Table II in the Data Supplement) . Blue Native Gel analysis showed that protein carbonylation was elevated in individual ETC components ( Figure III in the Data Supplement). These results indicated that the functional decline in AAA+ protease might be predominantly associated with reduced protein turnover and subsequent accumulation of oxidatively damaged proteins in the ETC in heart failure. 
Induction of Mitochondrial Catalase Restores AAA+ Protease Activity and Cardiac Contractility
To demonstrate the contribution of oxidative stress to AAA+ protease dysfunction and subsequent abnormal ETC protein homeostasis, we used a system that induced the overexpression of mCAT in mouse hearts ( Figure IVA in the Data Supplement). 10 An ≈20-fold increase in catalase activity was observed in the isolated mitochondria of induced mCAT transgenic (Tg) mouse hearts (Figure IVB in the Data Supplement). We injected tamoxifen 6 weeks after the TAC operation to induce mCAT ( Figure 5A ) and determined whether abolishing oxidative stress recovered proteolytic activity and abnormal protein homeostasis 2 weeks later. The overexpression of mCAT partially restored proteolytic activity to degrade fluorescein isothiocyanate-labeled casein in heart failure (Figure 5B) . Similar results were observed in the evaluation of endogenous protein degradation including the other ETC proteins, Ndufa9 and Cyc1, as well as COX5a ( Figure 5C ).
We also determined whether the enhancement in protein homeostasis contributed to histological and functional improvements. The late-stage and short-term induction of mCAT induced no alteration in interstitial fibrosis and cardiac hypertrophy at both the whole-heart and cardiomyocyte levels (Figure VA-VD in the Data Supplement). Although ROS signals have been shown to modulate angiogenesis under various conditions, 17 no significant differences were observed in capillary density in the myocardium (Figure VE in the Data Supplement). We then examined the functional integrity of the ETC and found that the mitochondrial oxygen consumption rates of complexes II and IV were improved ( Figure 6A ). We measured hydrogen peroxide release from heart mitochondria isolated from TACoperated failing hearts using 3-amino-1,2,4-triazole to eliminate the direct effect of induced catalase. The rate of hydrogen peroxide release measured in the presence of β-nicotinamide adenine dinucleotide hydrate (NADH) or succinate was attenuated by mCAT induction, whereas succinate-induced hydrogen peroxide generation maximally stimulated by the addition of antimycin A, a complex III inhibitor, was prominent ( Figure 6B ), which reflected the improved enzymatic activity of the respiratory complex. High-performance liquid chromatography studies ) once daily for 5 days 6 weeks after the transverse aortic constriction (TAC) operation. B, The fluorescein isothiocyanate casein assay was performed to assess the effect of mCAT induction on ATP-dependent proteolytic activity in isolated heart mitochondria (n=6-8 per group, duplicate experiments). C, Immunoblots to assess the ATP-dependent endogenous protein degradation of isolated mitochondria after the induction of mCAT. Data are shown as the means±SD (*P<0.05; ***P<0.001). i-mCAT indicates induced mCAT; and WT, wild type. were then conducted on cardiac tissues to determine changes in the energy state by mCAT induction. Compared with wild-type mice, induced mCAT Tg mice exhibited a marked improvement of phosphocreatine concentrations in TAC-operated heart failure. ATP contents were similar between these mice, although phosphocreatine /ATP ratios were significantly recovered by mCAT induction (Figure 6C ). Increased ETC protein levels did not contribute to energy production but promoted the ROS production in heart failure. The recovery of proteolysis in dysfunctional ETC proteins led to a reduction in the production of hydrogen peroxide and improved myocardial high-energy phosphate metabolism. Despite the absence of alterations in the histological examination, the antioxidant intervention led to mitochondrial bioenergetic improvements in heart failure. Consistent with these results, echocardiography revealed that cardiac contractility was improved even with slight changes in left ventricular size ( Figure 6D ).
Inhibition of LONP1 Negates the Protective Effects of mCAT Expression
We determined whether protective effects of mitochondrial catalase induction were mediated by proteolytic activity with the inhibition of LONP1. We used a siRNA-mediated in vivo knockdown strategy to inhibit specifically the expression of LONP1. The protein levels of LONP1 remarkably decreased in a timedependent manner in hearts of mice transfected with siRNA-targeting LONP1. The downregulation of LONP1 protein continued for 4 days and started to recover at 6 days ( Figure 7A ). Based on these results, siRNA injections were administrated once every 5 days starting on the first day of tamoxifen injections. The in vivo knockdown of LONP1 induced an ≈40% decrease in ATPdependent proteolytic activity in heart mitochondria ( Figure 7B ), which partially canceled the protective effects induced by mCAT on the mitochondrial oxygen consumption rate ( Figure 7C ) and cardiac contractility ( Figure 7D ). To strengthen our interpretation further, we used a wellknown cell-permeable protease and proteasome inhibitor, MG132 that has an inhibitory effect on the activity of LONP1 18 with the selective proteasome inhibitor, epoxomicin as an additional control. TAC-operated mice were infused with MG132, epoxomicin, or the carrier dimethyl sulfoxide for 2 weeks starting on the first day of tamoxifen injections. The infusion of MG132 induced a >30% reduction in ATPdependent proteolytic activity in isolated heart mitochondria ( Figure VIA and VIB in the Data Supplement). The preservation of mitochondrial oxygen consumption rate and cardiac function was diminished in MG132 treatment but not in epoxomicin treatment in induced mCAT Tg mice ( Figure VIC and VID in the Data Supplement). These results indicated that ameliorating oxidative stress recovered mitochondrial energy production and cardiac contractility, at least partially by restoring AAA+ protease activity.
Antioxidant Therapy Recovers Protease Activity and Mitochondrial Respiration
We determined whether a mitochondria-targeted antioxidant molecule had a therapeutic effect on a mouse model of pressure overload heart failure. TAC-operated mice were infused with mitoTEMPO, 11 a mitochondria-targeted superoxide dismutase mimetic for 2 and 6 weeks after surgery ( Figure 8A ). The infusion of mitoTEMPO restored the level of reduced cysteine in LONP1 and proteolytic activity to degrade fluorescein isothiocyanate-labeled casein ( Figure 8B and 8C). The ATPdependent endogenous protein degradation of isolated mitochondria also showed improved proteolysis ( Figure 8D ). This restored proteolytic activity ameliorated mitochondrial oxygen consumption by complexes II and IV ( Figure 8E ), which resulted in an increase in left ventricular contractile function ( Figure 8F ). These protective effects were partially eliminated by in vivo knockdown of LONP1.
Discussion
Functional integrity and appropriate responses to pathophysiological stimuli are required for mitochondria to meet cellular energy demands. Mitochondrial ETC is a main source of ROS; therefore, mitochondrial proteins are susceptible to oxidative modifications that impair protein function. The enzymatic repair and degradation of oxidized proteins are crucial to maintain mitochondrial integrity and cellular homeostasis. In the present study, we demonstrated for the first time that mitochondrial AAA+ protease activity was impaired in pressure overload heart failure in mice. The expression of AAA+ proteases was not decreased, and genetic antioxidant MitoTEMPO improved proteolytic activity and electron transport chain function in heart failure. A, Protocol of mitoTEMPO infusion. We delivered mitoTEMPO (700 μg kg −1 day −1 ) for 2 and 6 weeks after the transverse aortic constriction (TAC) operation. B, The extent of cysteine reduction in Lon protease homolog (LONP1) was evaluated with iodoacetamide. C, The fluorescein isothiocyanate casein assay was performed to assess the effect of mitoTEMPO on ATP-dependent proteolytic activity of isolated heart mitochondria (n=6-8 per group, duplicate experiments). D, Immunoblots to assess the ATP-dependent endogenous protein degradation of isolated mitochondria after mitoTEMPO infusion. E, The sequential state III oxygen consumption rate of isolated heart mitochondria (300 μg) was monitored with a fiber-optic system. Substrates and inhibitors were added sequentially at the final concentrations indicated as follows: FCCP (carbonylcyanide-p-trifluoromethoxyphenylhydrazone), 4 μmol/L carbonylcyanide-p-trifluoromethoxyphenylhydrazone; NADH, 0. intervention in mitochondria recovered proteolytic activity, which suggested that the OPTM of AAA+ proteases may have been responsible for decreasing proteolytic activity. This hypothesis was supported by the decreased level of reduced cysteine and increased level of carbonylation and nitrotyrosine in LONP1. The decline in AAA+ protease activity was closely associated with decreased protein turnover and increased oxidative damage in the ETC, leading to mitochondrial respiration deficiency and left ventricular contractile dysfunction. This is also the first study showing that mitoTEMPO treatment improved cardiac contractility in heart failure. The infusion of mitoTEMPO recovered the level of reduced LONP1 and ATP-dependent proteolytic activity. The cardioprotective effects of mitoTEMPO were at least partially eliminated by the loss of function of LONP1. These results indicate that the OPTM of AAA+ protease is the endogenous target for this small molecule used as a drug.
The decline in LONP1 activity has been well documented in aged mice. Although LONP1 expression levels increased in aged mouse hearts, AAA+ protease activity remained constant in heart mitochondria during aging. 19 Another study reported that AAA+ proteolytic activity decreased by 2.5-fold in the livers of 27-month-old rats with no concomitant changes in LONP1 protein expression levels. 20 These findings suggest that the efficiency of LONP1 may decrease with aging. Because oxidative stress is closely related with aging, especially in postmitotic tissues, persistent oxidative stress may be associated with a decrease in LONP1 activity. Evidently, both the ATPase and proteolytic activities of LONP1 were highly susceptible to oxidative inactivation when isolated rat brain mitochondria were treated with the reactive nitrogen species peroxynitrite. This inactivation preceded ETC dysfunction and was recovered with reduced glutathione addition. 21 These evidences indicate that LONP1 undergoes an age-related functional decline that may be mediated by oxidative modifications and that is likely to contribute to the accumulation of oxidatively inactivated proteins, similar to our findings in heart failure.
Not only AAA+ proteases but also proteasomes contribute to mitochondrial protein degradation. The autophagy machinery is involved in the elimination of whole mitochondria. 6, 22 In most mammalian cells, the UPS conducts ≈90% of intracellular proteolysis, ensuring that misfolded, oxidized, or damaged proteins are degraded. 23 There is compelling evidence for UPS activity in heart failure. Some studies on human biopsies from failing hearts reported the UPS dysfunction in heart failure, 23, 24 whereas an analysis in mice revealed the bidirectional alteration of UPS function in pressure overload heart failure. 25, 26 The proteasome substrate in mitochondria and its exporting mechanism are also poorly understood. The UPS was previously shown to be involved in the degradation of UCP2 in inner membrane or intermembrane space proteins. 22, 27 A recent study reported that some ETC proteins and TCA (tricarboxylic acid) cycle enzymes were susceptible to proteolysis by the 20S proteasome in vitro. 6 Although we observed no alterations in UPS function in TAC-induced heart failure, the UPS may be involved in ETC protein homeostasis.
We performed a comprehensive analysis to evaluate mitochondrial alterations in heart failure using a microarray and iTRAQ proteomics of purified mitochondria and showed that mitochondrial ETC protein levels were upregulated even with a reduction in the expression of their corresponding mRNAs. Proteomic alterations in mitochondria in heart failure have been investigated in different pathogeneses (myocardial infarction, pressure overload, and pacing-induced) and various severities (hypertrophied and decompensated) using different proteomic strategies (2-DE [2-dimension electrophoresis], DIGE [difference gel electrophoresis], and iTRAQ). 28 These investigations consistently revealed that fatty acid oxidation (FAO) enzymes were attenuated in a manner that was dependent on the progression of heart failure. [29] [30] [31] [32] In our study, FAO enzymes were downregulated at both the mRNA and protein level (data not shown). In contrast, alterations in ETC proteins have been inconsistently reported even among studies performed in pressure overload heart failure because of hypertension or aortic constriction. Some studies identified bidirectional changes in the ETC subunit composition. [29] [30] [31] [32] [33] However, a study using the same mouse model as our experiments reported that ETC protein levels were mostly increased in heart failure, 32 which is consistent with our results. In the present study, carbonylation, tyrosine nitration, and cysteine oxidation were enhanced in LONP1 in failing heart mitochondria. Under physiological conditions, ROS are constantly generated within cells and controlled at low concentrations, fluctuations that can affect many cellular functions through redox signaling. Cellular oxidative damage develops when ROS-generating systems overwhelm ROS-scavenging ones. OPTM can induce alterations in protein structures, leading to bidirectional effects on protein function. Some reversible modifications, such as S-glutathionylation and S-nitrosation, might play a dual role in protection against irreversible oxidation and the modulation of protein function. 15 Tyrosine nitration is an established marker for oxidative stress and cytotoxicity. Nitrotyrosine is relatively stable, and nitration often results in structural and functional abnormalities of proteins. 16 Protein carbonylation is an irreversible, nonenzymatic modification of proteins and is formed directly via the oxidation of side chains or indirectly via reactive carbonyl derivatives and aldehydes, leading to the loss of protein function. 15 Previous studies reported the detrimental effects of OPTM on the progression of heart failure. Cysteine sulfonylation and tyrosine nitration have been implicated in the pathophysiology of cardiac dysfunction in Gαq-induced cardiomyopathy. 34 A study using human biopsy samples demonstrated that carbonylation of proteasomes might contribute to defective protein degradation in human cardiomyopathies. 24 Our results provide additional evidence to support proteolytic systems being the target of OPTM in heart failure.
Oxidative stress has been implicated in the pathogenesis of many human diseases including cardiovascular diseases, whereas common antioxidants have proven ineffective in clinical trials. 35 One of the reasons is that these agents are not adequately delivered to the subcellular sites of ROS production. Recent experimental studies showed that treatments with the mitochondria-targeted antioxidant mitoTEMPO prevented hypertension and arrhythmic events in the setting of renin-angiotensin system activation 11, 36 and reduced diabetes mellitus-attributable mortality after myocardial infarction. 12 This study provides evidence that this agent improves cardiac function even during the late stage of pressure overload, albeit to a modest degree. Oxidatively inactivated mitochondrial AAA+ proteases might be a target of mitoTEMPO treatment. A greater protective effect might be observed by a more longterm treatment from the early stage. A recent study reported that other mitochondria-targeted antioxidant peptides attenuated TAC-induced heart failure and proteomic alterations of mitochondria, demonstrating the effectiveness of selective delivery to mitochondria. 37 
